PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10608722-6	1999	Bradykinin levels during LDL apheresis tended to be higher with losartan than without losartan (without versus with, 529 +/- 121 [n = 4, mean +/- SE] pg/ml vs. 1,058 +/- 49 at the 2,000 ml stage, p < 0.01).	Losartan	64-72	kininogen 1	Homo sapiens	0-10	
15655136-0	2005	Losartan increases bradykinin levels in hypertensive humans.	Losartan	0-8	kininogen 1	Homo sapiens	19-29	
15655136-5	2005	Losartan increased blood levels of BK-(1-9) and hydroxylated BK-(1-9) by approximately 2-fold and reduced the BK-(1-7)/BK-(1-9) ratio by 55%.	Losartan	0-8	kininogen 1	Homo sapiens	35-37	
15655136-5	2005	Losartan increased blood levels of BK-(1-9) and hydroxylated BK-(1-9) by approximately 2-fold and reduced the BK-(1-7)/BK-(1-9) ratio by 55%.	Losartan	0-8	kininogen 1	Homo sapiens	61-63	
15655136-5	2005	Losartan increased blood levels of BK-(1-9) and hydroxylated BK-(1-9) by approximately 2-fold and reduced the BK-(1-7)/BK-(1-9) ratio by 55%.	Losartan	0-8	kininogen 1	Homo sapiens	61-63	
15655136-12	2005	CONCLUSIONS: Losartan increases bradykinin levels.	Losartan	13-21	kininogen 1	Homo sapiens	32-42	
12706934-8	2003	The increases in CBF induced by BK in the perindopril and losartan groups were significantly greater than those in the control group.	Losartan	58-66	kininogen 1	Homo sapiens	32-34	
12706934-11	2003	CONCLUSIONS: Perindopril and losartan similarly augment BK-induced coronary vasodilation.	Losartan	29-37	kininogen 1	Homo sapiens	56-58	
12706934-12	2003	Perindopril may have a greater potential to enhance the BK-induced coronary release of t-PA than losartan.	Losartan	97-105	kininogen 1	Homo sapiens	56-58	
11433227-10	2001	BK caused a transient increase in [Ca2(+)]i, which was significantly decreased by ANG II; concurrent addition of Losartan and PD 123319 prevented ANG II effect.	Losartan	113-121	kininogen 1	Homo sapiens	0-2	
19944371-11	2009	The reduction in BKN-dependent relaxation was prevented by treatment for 1 month with the antioxidant N-acetylcysteine (1 g.kg.day), or losartan, an Ang II type 1 receptor blocker (10 mg.kg.day).	Losartan	136-144	kininogen 1	Homo sapiens	17-20	
11675956-5	2001	Although angiotensin II and bradykinin plasma levels during LDL apheresis were significantly greater with losartan than without, blood pressure reduction by losartan was mild and unpleasant symptoms were not induced.	Losartan	106-114	kininogen 1	Homo sapiens	28-38	
11675956-7	2001	The greater rise in bradykinin levels during apheresis with losartan might be ascribable to angiotensin type 2-receptor stimulation.	Losartan	60-68	kininogen 1	Homo sapiens	20-30	
10608722-6	1999	Bradykinin levels during LDL apheresis tended to be higher with losartan than without losartan (without versus with, 529 +/- 121 [n = 4, mean +/- SE] pg/ml vs. 1,058 +/- 49 at the 2,000 ml stage, p < 0.01).	Losartan	86-94	kininogen 1	Homo sapiens	0-10	
10411851-0	1999	Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure.	Losartan	49-57	kininogen 1	Homo sapiens	8-18	
10411851-5	1999	Bradykinin caused profound vasodilatation after enalapril (peak, 357+/-67%) and less after losartan (peak, 230+/-46%).	Losartan	91-99	kininogen 1	Homo sapiens	0-10	
35573493-3	2022	Angiotensin receptor blockers (ARBs) such as losartan, however, are not known to increase bradykinin levels and, therefore, this complication is not as widely recognized.	Losartan	45-53	kininogen 1	Homo sapiens	90-100	
9012741-10	1997	The association of losartan (10 mumol/L) with the bradykinin B2 receptor antagonist HOE 140 (1 mumol/L) totally prevented the relaxation due to the ACEI.	Losartan	19-27	kininogen 1	Homo sapiens	50-60	
7505360-6	1993	In human forearm vasculature, oral losartan (20-100 mg) inhibits vasoconstriction to ANG I and ANG II without significantly influencing bradykinin-induced vasodilation, whereas enalapril selectively inhibits ANG I-induced vasoconstriction while potentiating the vasodilator effect of bradykinin.	Losartan	35-43	kininogen 1	Homo sapiens	284-294	
8391072-2	1993	Since ACE inactivates bradykinin in addition to its action on angiotensin I we hypothesized that losartan and enalapril have different effects on the response to angiotensin and bradykinin.	Losartan	97-105	kininogen 1	Homo sapiens	22-32	
8391072-2	1993	Since ACE inactivates bradykinin in addition to its action on angiotensin I we hypothesized that losartan and enalapril have different effects on the response to angiotensin and bradykinin.	Losartan	97-105	kininogen 1	Homo sapiens	178-188	
28700653-8	2017	In longitudinal analyses, higher bradykinin was associated with preservation of surface density of the peripheral glomerular basement membrane (partial r = 0.162, P = 0.013), and for participants randomized to losartan, higher hyp3-bradykinin (1-8) was associated with more limited increase in cortical interstitial fractional volume (partial r = -0.291, P = 0.033).	Losartan	210-218	kininogen 1	Homo sapiens	33-43